Posted by Michael Wonder on 16 Jan 2017
SMC - January 2017 decisions
16 January 2017 - The Scottish Medicines Consortium has today published advice accepting four new medicines for routine use in NHS Scotland.
Pembrolizumab (Keytruda) was accepted for the treatment of late-stage non-small cell lung cancer. It was considered through SMC’s Patient and Clinician Engagement process, for medicines used at the end of life and for very rare conditions.
Deferasirox (Exjade) was accepted for treatment of an excess of iron in the body resulting from frequent blood transfusions in some patients with a rare blood disorder known as myelodysplastic syndrome.
Elbasvir with grazoprevir (Zepatier) was accepted for the treatment of chronic Hepatitis C. Elbasvir with grazoprevir is a combination of two medicines that inhibit the replication of the hepatitis C virus and offers the prospect of a cure for hepatitis C infection.
